Cell and gene therapies are moving rapidly from the research pipeline into real-world care—bringing extraordinary promise for patients and significant clinical and financial complexity for self-insured employers.

As these therapies become more prevalent, HR and benefits leaders are navigating a new set of questions with limited precedent: how to support employee access to breakthrough treatments, how to manage financial exposure and oversight, and how to prepare benefit strategies for a category of care still taking shape.

 In this webinar, industry leaders will offer clarity on how employers can begin to think strategically about readiness, governance, and long-term sustainability—highlighting what matters most today and which capabilities will grow in importance as cell and gene therapies emerge as a distinct high-cost category.

What You’ll Learn

- Why cell and gene therapies represent a unique and growing challenge for self-insured employers

- Key considerations employers should evaluate before a cell or gene therapy claim arises

- How to approach access, oversight, and financial confidence in an evolving care landscape

- What a benefits “playbook” for cell and gene therapies may include as this category develops

From Day One is a Recertification Provider for SHRM and HRCI. This session is eligible for 1 PDC. The Activity ID will be sent to attendees after the conclusion of the session.

This session is hosted by the From Day One editorial team with support from Quantum Health.